Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2023 | 12-2022 | 12-2021 | 12-2020 | 12-2019 | |
Cash Flows From Operating Activities | |||||
Net Income | 8,572,000 | 6,049,000 | 24,018,000 | 8,071,000 | 7,147,000 |
Depreciation Amortization | 8,383,000 | 6,965,000 | N/A | 6,129,000 | 5,788,000 |
Income taxes - deferred | 551,000 | 1,128,000 | N/A | 1,807,000 | 1,793,000 |
Accounts receivable | N/A | N/A | -389,000 | 137,000 | -980,000 |
Accounts payable and accrued liabilities | N/A | N/A | -21,000 | -324,000 | 553,000 |
Other Working Capital | -1,903,000 | -1,570,000 | -878,000 | -2,728,000 | -725,000 |
Other Operating Activity | -1,145,000 | 1,664,000 | -7,659,000 | 558,000 | 49,000 |
Operating Cash Flow | $14,458,000 | $14,236,000 | $15,071,000 | $13,650,000 | $13,625,000 |
Cash Flows From Investing Activities | |||||
Change In Deposits | 10,607,000 | 4,662,000 | -14,105,000 | -1,408,000 | 2,333,000 |
PPE Investments | -823,000 | -758,000 | -1,138,000 | -1,187,000 | -522,000 |
Net Acquisitions | -4,681,000 | -1,276,000 | 20,102,000 | -10,091,000 | -4,925,000 |
Purchase Of Investment | -117,000 | -139,000 | -191,000 | -230,000 | -302,000 |
Sale Of Investment | 348,000 | 133,000 | 442,000 | 723,000 | 1,152,000 |
Purchase Sale Intangibles | 262,000 | -1,153,000 | -845,000 | -930,000 | 95,000 |
Other Investing Activity | 262,000 | -1,154,000 | -902,000 | -989,000 | 38,000 |
Investing Cash Flow | $5,596,000 | $1,468,000 | $4,208,000 | $-13,182,000 | $-2,226,000 |
Cash Flows From Financing Activities | |||||
Change In Short Term Borrowing | 546,000 | 252,000 | -3,524,000 | 2,261,000 | -1,582,000 |
Debt Issued | N/A | N/A | 16,000 | 7,126,000 | 93,000 |
Debt Repayment | -2,223,000 | -2,575,000 | -2,162,000 | -2,003,000 | -3,195,000 |
Common Stock Issued | 153,000 | 100,000 | 53,000 | N/A | 201,000 |
Common Stock Repurchased | -8,719,000 | -10,652,000 | -3,057,000 | -2,842,000 | -5,533,000 |
Dividend Paid | -7,255,000 | -7,506,000 | -7,368,000 | -6,987,000 | -6,645,000 |
Other Financing Activity | 3,220,000 | -181,000 | -222,000 | 237,000 | 3,034,000 |
Financing Cash Flow | $-14,278,000 | $-20,562,000 | $-16,264,000 | $-2,208,000 | $-13,627,000 |
Exchange Rate Effect | 100,000 | -32,000 | -266,000 | 286,000 | 69,000 |
Beginning Cash Position | 7,517,000 | 12,407,000 | 9,658,000 | 11,112,000 | 13,271,000 |
End Cash Position | 13,393,000 | 7,517,000 | 12,407,000 | 9,658,000 | 11,112,000 |
Net Cash Flow | $5,876,000 | $-4,890,000 | $2,749,000 | $-1,454,000 | $-2,159,000 |
Free Cash Flow | |||||
Operating Cash Flow | 14,458,000 | 14,236,000 | 15,071,000 | 13,650,000 | 13,625,000 |
Capital Expenditure | -1,060,000 | -916,000 | -1,378,000 | -1,275,000 | -1,379,000 |
Free Cash Flow | 13,398,000 | 13,320,000 | 13,693,000 | 12,375,000 | 12,246,000 |